在炎症性疾病中的TNFR2信号.
Richard O Williams1, Felix Il Clanchy1, Yi-Shu Huang1
1Kennedy Institute of Rheumatology, University of Oxford, Roosevelt Drive, Oxford, OX3 7FY, UK.
Best practice & research. Clinical rheumatology
|March 27, 2024
概括
选择性向瘤亡因子 (TNF) 受体提供了新的治疗策略. 抑制TNFR1可以治疗自身免疫性疾病,而TNFR2激动剂可以帮助癌症治疗.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 瘤亡因子 (TNF) 通过两个受体发出信号:TNFR1和TNFR2.
- TNFR1调解促炎效应,而TNFR2参与免疫平衡和组织愈合,以及瘤进展.
- 目前的抗TNF生物药物缺乏选择性,抑制TNFR1和TNFR2.
研究的目的:
- 探索选择性TNF受体抑制剂的治疗潜力.
- 研究自身免疫性疾病的TNFR1抑制和癌症的TNFR2抑制.
- 评估TNFR2激动剂作为一种潜在的治疗方法.
主要方法:
- 该研究假设在自身免疫性疾病中TNFR1的选择性抑制.
- 它探讨了TNFR1选择性抑制剂和TNFR2特异性激动剂的发展.
- 该研究讨论了这些概念对于新的治疗策略的验证.
主要成果:
- 选择性TNFR1抑制被假设可以缓解炎症并促进自身免疫性疾病中的平衡.
- 建议TNFR2信号传递能够不受阻碍地进行TNFR1抑制,从而有助于稳态.
- 目前正在研究TNFR2特异性激动剂,用于单一治疗或组合治疗.
结论:
- 选择性抑制TNF受体是一个有前途的治疗途径.
- 通过减少炎症,TNFR1对抗剂可以治疗自身免疫疾病.
- TNFR2激动剂可能为癌症治疗提供新的策略.
相关概念视频
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Inflammatory Response
2.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.0K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K


